Biotechnology company developing allogeneic, off-the-shelf iPSC-based cell therapies and automated manufacturing processes for degenerative diseases
Biotechnology company developing allogeneic, off-the-shelf iPSC-based cell therapies and automated manufacturing processes for degenerative diseases. Its pipeline includes iPSC-derived cardiomyocyte therapies for advanced heart failure and acute myocardial infarction, as well as programs for osteoporosis and dry age-related macular degeneration.